Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones

Jörg B. Engel, Andrew V. Schally, Johannes Dietl, Lorenz Rieger, Arnd Höni

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

Gynecological cancers such as breast, ovarian, and endometrial carcinoma express receptors for luteinizing hormone-releasing hormone (LHRH), bombesin/gastrin-releasing peptide (BN/GRP), and somatostatin (SST). These tumors are therefore suitable candidates for targeted therapy with cytotoxic hybrid molecules consisting of a cytotoxic radical and a peptide hormone analogue as a carrier. These compounds have been shown to be more active and less toxic in vivo than nontargeted chemotherapy in models of various human cancers which express the respective receptors. The current review summarizes experimental and clinical findings with cytotoxic peptide hormone analogues of LHRH (AN-152 [AEZS 108], AN-207), BN/GRP (AN-215), and SST (AN-238) in breast, ovarian, and endometrial cancers.

Original languageEnglish (US)
Pages (from-to)652-658
Number of pages7
JournalMolecular Pharmaceutics
Volume4
Issue number5
DOIs
StatePublished - Sep 1 2007

Keywords

  • AN-152 [AEZS 108]
  • AN-207
  • AN-215
  • AN-238
  • Bombesin
  • Cytotoxic peptide analogues
  • LHRH
  • Somatostatin
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones'. Together they form a unique fingerprint.

  • Cite this